CRISPR Therapeutics AG (CRSP) EBITDA (2015 - 2026)

CRISPR Therapeutics AG has disclosed EBITDA across 12 years of filings, most recently posting -$129.7 million for Q1 2026.

• EBITDA for Q1 2026 came in at -$129.7 million, up 3.0% year-over-year; the trailing twelve-month figure through Mar 2026 was -$574.6 million (down 51.23% YoY), and the FY2025 annual result was -$578.6 million, down 57.95% from the prior year.
• EBITDA came in at -$129.7 million for Q1 2026 at CRISPR Therapeutics AG, up from -$130.8 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $98.1 million in Q4 2023 to a low of -$208.6 million in Q2 2025.
• The 5-year median for EBITDA is -$120.1 million (2024), against an average of -$110.1 million.
• Across the five-year window, EBITDA jumped 194.32% in 2023 and plunged 184.08% in 2025, its largest moves.
• CRISPR Therapeutics AG's EBITDA stood at -$104.0 million in 2022, then surged by 194.32% to $98.1 million in 2023, then slumped by 146.95% to -$46.0 million in 2024, then tumbled by 184.08% to -$130.8 million in 2025, then climbed by 0.83% to -$129.7 million in 2026.
• The last three EBITDA figures came in at -$129.7 million (Q1 2026), -$130.8 million (Q4 2025), and -$105.5 million (Q3 2025), per Business Quant data.